First AD

Second AD

Pirtobrutinib in the Management of R/R CLL: Updates from the BRUIN Trial

Video content above is prompted by the following:

To briefly review the non-covalent BTKi pirtobrutinib and BRUIN data.

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Optimizing R/R CLL Treatment: Therapy Sequencing and Supportive Care Strategies

Panelists discuss how the non-covalent BTK inhibitor pirtobrutinib has shown promising results in the BRUIN clinical trials for both BTK inhibitor-naive and previously treated chronic lymphocytic leukemia patients, reviewing key efficacy and safety data presented at recent hematology conferences.

The Current Treatment Landscape for R/R CLL

Impact of Prior BTKi vs BCL2i Therapy on Treatment Decision-Making in CLL 